June 1, 2018
Takeda Pharmaceutical and ASKA Pharmaceutical said on May 31 that they have entered into a licensing agreement for Takeda’s gonadotropin-releasing hormone (GnRH) receptor antagonist relugolix for women’s health indications. With the deal, Takeda will grant ASKA exclusive rights in Japan...read more